Chimeric Therapeutics (ASX:CHM) has announced that the first patient in its Phase 1B clinical trial in recurrent and/or progressive glioblastoma multiforme (GBM) had received CHM 1101 CAR T cell treatment.
CHM 1101 is a first-in-class, autologous Chlorotoxin CAR-T cell therapy currently being investigated in patients with recurrent and/or progressive glioblastoma.
The first patient in the Phase 1B clinical trial was dosed at the Sarah Cannon Transplant and Cellular Therapy Program at St. David’s South Austin Medical Center in Texas. The patient received CHM 1101 therapy as second-line therapy.
“We are very excited to have initiated the first patient at St David’s Austin Medical Center,” said Jason Litten, managing director and chief medical officer of Chimeric Therapeutics.
“We are looking forward to building off our recently released positive Phase 1A clinical data and advancing the clinical development of this unique and potentially transformative cell therapy for patients with this devastating disease.”
“We are thrilled to have reached this key milestone for Chimeric and the advancement of the CHM 1101 clinical development program,” said Jennifer Chow, CEO and managing director of Chimeric Therapeutics. “We believe that the full potential of CHM 1101 for patients with recurrent and/ or progressive glioblastoma will only be unlocked through the advancement of our clinical development program and look forward to continuing to advance this trial forward.”